Install Sina Finance client to receive the most comprehensive market information at the first time →【 Download address 】
Gilead said Thursday that its twice yearly experimental HIV vaccine is 100% effective in later trials.
The company said that the late test results showed that none of the approximately 2000 women who received the Gilead vaccine lenacapavir were infected with HIV through the mid-term analysis. This prompted the Independent Data Monitoring Committee to recommend Gilead to blind the Phase 3 trial and provide treatment to everyone in the study. Other participants received standard daily medication.
These results make Gilead one step closer to introducing a new form of pre exposure prevention (PrEP) and expanding its HIV business.
Driven by the above news, Geely's share price rose about 7% on Thursday.
Jared Baeten, vice president of HIV clinical development of Gilead, said: "What the world needs is that people have more choices of PrEP, so that they can choose the best choice for them."
Massive information, accurate interpretation, all in Sina Finance APP
Editor in charge: Zhang Jun SF065
